Modafinil Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 100 mg, 200 mg, 150 mg, 250 mg
Reference Brands: Provigil, Modalert, Armodafinil(US & EU)
Category:
Neurology
Modafinil is a wakefulness-promoting agent that enhances alertness by stimulating the central nervous system. It inhibits the reuptake of dopamine, increasing its availability. Benefits include improved focus, reduced sleepiness, increased alertness, and enhanced cognitive function, supporting treatment of narcolepsy, shift work disorder, and excessive daytime sleepiness.
Modafinil tablet is available in Tablet
and strengths such as 100 mg, 200 mg, 150 mg, 250 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Modafinil tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Modafinil tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Modafinil tablets, marketed as Provigil, are approved in the US by the FDA and in the EU via EMA for narcolepsy, shift work sleep disorder, and excessive daytime sleepiness. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and manufacturing documents, while the EMA ensures compliance with regional standards.
Modafinil is a central nervous system (CNS)–active medication widely used to manage disorders related to excessive sleepiness. It is commonly prescribed for conditions such as narcolepsy, obstructive sleep apnea–related daytime sleepiness, and shift work sleep disorder. By promoting wakefulness and improving alertness, Modafinil helps patients maintain normal daily activities and productivity. The medicine is typically administered orally in tablet form and is well recognized in sleep medicine for its effectiveness in improving daytime functioning.
Modafinil works by influencing certain neurotransmitters in the brain that regulate the sleep–wake cycle. Unlike traditional stimulants, it has a lower potential for causing extreme stimulation, making it a preferred option in many clinical settings. Due to its efficacy and safety profile, Modafinil is considered a first-line treatment for narcolepsy in several countries, including the United States and many European nations.
Today, Modafinil is widely available under different brand names across global pharmaceutical markets and is commonly listed under neurology and sleep disorder treatment categories in medical and pharmaceutical platforms.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing